Valence8 US LP
- SEC CIK
- 0001943819
- Latest filing
- Aug 6, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 12, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 10
- −30 vs. Q3 2024
- Portfolio value
- $208.2M
- −$21.2M (−9.2%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| iShares MSCI USA Quality Factor ETF46432F339 | ETF | 326,910 | $58.2M | 28.0% | −10,562−3.1% | Reduced | – |
| Invesco QQQ Trust Series I46090E103 | ETF | 83,798 | $42.8M | 20.6% | −4,351−4.9% | Reduced | – |
| iShares Tr46434V456 | MSCI INTL QUALTY | 990,439 | $36.8M | 17.7% | −35,851−3.5% | Reduced | – |
| iShares Tr464288877 | EAFE VALUE ETF | 404,248 | $21.2M | 10.2% | +5,062+1.3% | Added | – |
| Vanguard Morningstar Value ETF922908744 | ETF | 97,398 | $16.5M | 7.9% | +768+0.8% | Added | – |
| State Street Consumer Staples Select Sector SPDR ETF81369Y308 | ETF | 166,161 | $13.1M | 6.3% | +894+0.5% | Added | – |
| iShares Tr464287515 | EXPANDED TECH | 77,909 | $7.80M | 3.7% | +77,909 | New | – |
| iShares Tr46435G334 | MSCI UK ETF NEW | 116,688 | $3.96M | 1.9% | −92,656−44.3% | Reduced | – |
| State Street Utilities Select Sector SPDR ETF81369Y886 | ETF | 52,247 | $3.95M | 1.9% | +307+0.6% | Added | – |
| iShares Inc46434G822 | MSCI JAPAN ETF | 58,649 | $3.94M | 1.9% | −49,985−46.0% | Reduced | – |
Sold out since Q3 2024 (31)
Positions held at the end of Q3 2024 that are gone from this filing.
| Security | Class | Shares in Q3 2024 | Value in Q3 2024 | % of portfolio in Q3 2024 | History |
|---|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | SHS USD | 8,969 | $999.2K | 0.4% | History |
| BMYBristol Myers Squibb Co | Stock | 17,785 | $920.2K | 0.4% | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 4,585 | $684.6K | 0.3% | History |
| INSMINSMED Inc | COM PAR $.01 | 7,865 | $574.1K | 0.3% | History |
| INDVIndivior Pharmaceuticals, Inc. | ORD | 57,293 | $564.2K | 0.2% | History |
| LLYEli Lilly & Co | Stock | 633 | $560.8K | 0.2% | History |
| ARGXArgenx SE | SPONSORED ADR | 953 | $516.6K | 0.2% | History |
| SLNOSoleno Therapeutics Inc | COM | 9,706 | $490.1K | 0.2% | History |
| KROSKeros Therapeutics, Inc. | COM | 8,025 | $466.0K | 0.2% | History |
| NUVLNuvalent, Inc. | COM | 4,115 | $421.0K | 0.2% | History |
| JANXJanux Therapeutics, Inc. | COM | 7,857 | $356.9K | 0.2% | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 6,684 | $341.6K | 0.1% | History |
| TYRATyra Biosciences, Inc. | COM | 13,188 | $310.1K | 0.1% | History |
| APGEApogee Therapeutics, Inc. | COM | 5,240 | $307.8K | 0.1% | History |
| PCVXVaxcyte, Inc. | COM | 2,468 | $282.0K | 0.1% | History |
| NTLAIntellia Therapeutics, Inc. | COM | 13,020 | $267.6K | 0.1% | History |
| VIRVir Biotechnology, Inc. | COM | 33,650 | $252.0K | 0.1% | History |
| BPMCBlueprint Medicines Corp | COM | 2,618 | $242.2K | 0.1% | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 4,241 | $235.6K | 0.1% | History |
| ENTAEnanta Pharmaceuticals Inc | COM | 19,939 | $206.6K | 0.1% | History |
| RLAYRelay Therapeutics, Inc. | COM | 26,200 | $185.5K | 0.1% | History |
| ZVRAZevra Therapeutics, Inc. | COM NEW | 21,596 | $149.9K | 0.1% | History |
| ERASErasca, Inc. | COM | 46,923 | $128.1K | 0.1% | History |
| SLDBSolid Biosciences Inc. | COM NEW | 15,728 | $109.6K | <0.1% | History |
| VTGNVistagen Therapeutics, Inc. | COM | 34,376 | $103.5K | <0.1% | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 17,495 | $71.0K | <0.1% | History |
| ALECAlector, Inc. | COM | 14,708 | $68.5K | <0.1% | History |
| CLYMClimb Bio, Inc. | COM | 12,045 | $61.3K | <0.1% | History |
| CYPHCypherpunk Technologies Inc. | COM NEW | 18,511 | $47.6K | <0.1% | History |
| NKTRNektar Therapeutics | COM | 26,107 | $33.9K | <0.1% | History |
| KZRKezar Life Sciences, Inc. | COM | 21,136 | $16.3K | <0.1% | History |